Gri bio announces reverse stock split

Gri's common stock is expected to begin trading on a post-split adjusted basis on january 30, 2024 la jolla, ca, jan. 26, 2024 (globe newswire) -- gri bio, inc. (nasdaq: gri) (“gri bio” or the “company”), a biotechnology company advancing an innovative pipeline of natural killer t (“nkt”) cell modulators for the treatment of inflammatory, fibrotic and autoimmune diseases, today announced that the board of directors of the company approved a 1-for-7 reverse stock split (the “reverse split”) of the company's common stock. the reverse split was approved by the stockholders of the company at a special meeting of the company held on january 19, 2024.
GRI Ratings Summary
GRI Quant Ranking